Latest news and insights on the pharmaceutical industry | Indian Pharma Post
Policy
Policy | 19 March 2025

Anupriya Patel inaugurates India Innovation Summit – Pioneering Solutions to End TB

TB treatment coverage in India increased by 32% in the last eight years from 53% in 2015 to 85% in 2023

Policy
Policy | 07 March 2025

India’s biotech economy set to reach a massive $300 bn by 2030: Dr. Jitendra Singh

Biotech potential of Himalayan territories including Jammu & Kashmir, particularly their agri-biotech potential remains still under-explored

Policy
Policy | 05 March 2025

Need for enhancing capacity building of medical officers to achieve desired results of healthcare schemes at the grassroot level: J. P. Nadda

Nadda also commended the role of ASHA workers, “grassroot foot soldiers”, in the healthcare system

Policy
Policy | 03 March 2025

PMBJP has led to a total savings of Rs. 30,000 crore for citizens: Health Minister Nadda

In financial year 2024-25, PMBJP has made sales of Rs. 1,760 crore (at MRP) till Feb 2025

Policy
Policy | 23 February 2025

5.1 lakh TB patients notified across India

Among those identified, 2.4 lakh patients have been notified from public health institutions, while 1.1 lakh were identified through private healthcare facilities

Policy
Policy | 06 February 2025

India reaffirms commitment to global pharmaceutical standardization and regulatory convergence: Anupriya Patel

International Meeting of World Pharmacopoeias serves as a vital platform to foster international collaboration in pharmacopoeial science and regulatory harmonization

Policy
Policy | 01 February 2025

Budget 2025: Industry welcomes customs duty exemptions on 36 life-saving drugs and medicines

The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25

Policy
Policy | 23 January 2025

Budget 2025: Industry expects tax incentives and thrust on affordable healthcare

Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials

Policy
Policy | 16 January 2025

USFDA will no longer allow for use of FD&C Red No. 3 in food and ingested drugs

The FDA determined that the data presented in a 2022 color additive petition show that this ingredient causes cancer in male laboratory rats exposed to high levels of FD&C Red No. 3 because of a hormonal mechanism that occurs in male rats

Policy
Policy | 11 January 2025

Genome India Project marks a defining moment for country's biotechnology landscape: Modi

Modi remarked that more than 20 illustrious research institutions such as IISc, IITs, CSIR and DBT-BRIC have played a major role in this research

Policy
Policy | 07 January 2025

1.48 lakh new TB cases identified in the first 30 days of TB Mukt Bharat -100 Days Intensified Campaign

Nadda chairs Joint Strategy Meeting with Line Ministries for TB Mukt Bharat Abhiyan- 100-Day Intensified Campaign

Policy
Policy | 20 December 2024

India is the fourth largest medical devices market in Asia: Anupriya Patel

The segment has immense growth potential driven by the country's increasing healthcare needs, technological innovations, government support, and emerging market opportunities

Policy
Policy | 16 December 2024

Pharmaceuticals & Medical Devices Bureau of India partnered with cooperative sector to open Jan Aushadhi Kendras through PACS

Till 30th November 2024, more than 2690 PACS have been given initial approval and 687 Kendras have been opened in PACS

Policy
Policy | 30 October 2024

MRP of anti-cancer drugs to come down due to custom duty exemption and GST rate reduction

This is in pursuance to the announcement made in the Union Budget for the year 2024-25 exempting these three anti-cancer medicines from customs duty

Policy
Policy | 21 October 2024

Health Minister Nadda inaugurates Medicine Update BJMFCON 2024

Infant Mortality Rate in Bihar came down from 42 to 27 in 2020, and in Jharkhand, from 34 to 25 in 2020

Policy
Policy | 14 October 2024

CDSCO, NRAI meets WHO international standards for vaccine regulations

India has been declared ‘functional’ against all the core regulatory functions of the WHO Global Benchmarking Tool Version VI

Policy
Policy | 09 October 2024

Biocon Biologics’ sponsored report suggests ways to increase adoption of Biosimilars in poor countries

Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines

Policy
Policy | 28 September 2024

India releases revised operational guidelines of non-alcoholic fatty liver disease

India has taken the lead in recognising NAFLD as a major non-communicable disease

Policy
Policy | 28 September 2024

India reaffirms commitment to social determinants of health at UNGA

India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting

Policy
Policy | 27 September 2024

India highlights need for global cooperation to address AMR threat at UNGA

AMR poses a critical threat to global public health undermining decades of progress made in the field of modern medicine

Startup

Digitization